Equity capital markets

BioLineRx Announces $6 Million Registered Direct Offering

Retrieved on:

Monday, April 1, 2024

Patient, Sale, Multiple myeloma, Attention, American depositary receipt, ADS, Security (finance), Prospectus, Pancreatic cancer, BioLineRx, Equity capital markets, File, TEL

Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx.

Key Points:

Each ADS represents fifteen (15) ordinary shares, par value NIS 0.10 per share, of BioLineRx.
The offering is expected to close on or about April 1, 2024, subject to the satisfaction of customary closing conditions.
The gross proceeds from the offering (without taking into account any proceeds from any future exercises of warrants), before deducting the placement agent's fees and other offering expenses payable by the Company, are expected to be $6.0 million.
The offering is being made by the Company pursuant to its shelf registration statement on Form F-3 (File No.

MADISON INTERNATIONAL REALTY EXPANDS GLOBAL PRESENCE WITH NEW OFFICE IN SINGAPORE

Retrieved on:

Monday, April 1, 2024

Equity capital markets, Growth, History

NEW YORK, April 1, 2024 /PRNewswire/ -- Madison International Realty, a leading real estate private equity firm, has opened its office in Singapore, establishing a presence in the Asia-Pacific region.

Key Points:

NEW YORK, April 1, 2024 /PRNewswire/ -- Madison International Realty, a leading real estate private equity firm, has opened its office in Singapore, establishing a presence in the Asia-Pacific region.
Establishing a formal office in Singapore brings us closer to our valued investors and enables us to explore new opportunities," said Ronald Dickerman, Founder and President of Madison International Realty.
"Our increased presence in Singapore strengthens our global footprint and on-the-ground presence in the Asia-Pacific region," added Dickerman.
For more information about Madison International Realty and its new Singapore office, please visit https://madisonint.com .

Akero Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares

Retrieved on:

Friday, March 8, 2024

The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $366.9 million.

Key Points:

The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $366.9 million.
J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI acted as joint book-running managers for the offering.
The shares of common stock were offered by Akero pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC).
A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on March 6, 2024.

ADT Announces Pricing of Secondary Public Offering of Common Stock and Concurrent Share Repurchase

Retrieved on:

Thursday, March 7, 2024

The underwriters will have a 30-day option to purchase up to an additional 9,750,000 shares of common stock from the Selling Stockholders.

Key Points:

The underwriters will have a 30-day option to purchase up to an additional 9,750,000 shares of common stock from the Selling Stockholders.
The Company is not selling any shares and will not receive any proceeds from the offering.
In addition, ADT has authorized the concurrent purchase from the underwriters of 15,000,000 shares of common stock as part of the secondary public offering (the “Share Repurchase”) subject to the completion of the offering.
The Share Repurchase is part of the Company’s existing $350 million share repurchase program.

ADT Announces Launch of Secondary Public Offering of Common Stock and Concurrent Share Repurchase

Retrieved on:

Wednesday, March 6, 2024

Varick Street, Share repurchase, Morgan Stanley, Attention, Prospectus, Telephone, RBC Capital Markets, 2nd Floor, EDGAR, ADT, Sale, Equity capital markets, Apollo Global Management, BOCA, Broadridge Financial Solutions, Security (finance), Commission, Barclays, Vesey Street

The underwriters will have a 30-day option to purchase up to an additional 8,250,000 shares of common stock from the Selling Stockholders.

Key Points:

The underwriters will have a 30-day option to purchase up to an additional 8,250,000 shares of common stock from the Selling Stockholders.
The Company is not selling any shares and will not receive any proceeds from the proposed offering.
In addition, ADT has authorized the concurrent purchase from the underwriters of 15,000,000 shares of common stock as part of the secondary public offering (the “Share Repurchase”) subject to the completion of the offering.
The Share Repurchase is part of the Company’s existing $350 million share repurchase program.

BridgeBio Pharma Announces Pricing of Public Offering of Common Stock

Retrieved on:

Wednesday, March 6, 2024

PALO, Attention, J.P. Morgan & Co., Prospectus, Capital market, Telephone, Cancer, File, Sale, Exercise, Equity capital markets, Form, Broadridge Financial Solutions, Mizuho Securities, 3rd Floor, Security (finance)

PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering price of $29.00 per share, before deducting underwriting discounts and commissions.

Key Points:

PALO ALTO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio”), a commercial-stage biopharmaceutical company focused on genetic diseases and cancers, today announced the pricing on March 5, 2024 of an underwritten public offering of 8,620,690 shares of its common stock at a public offering price of $29.00 per share, before deducting underwriting discounts and commissions.
In addition, BridgeBio has granted the underwriters a 30-day option to purchase up to an additional 1,293,103 shares of its common stock on the same terms and conditions.
All of the shares in the offering to be sold by BridgeBio.
The shares of common stock are being offered by BridgeBio pursuant to an effective shelf registration statement on Form S-3ASR (File No.

Viper Energy Announces Pricing of Secondary Common Stock Offering by Diamondback Energy, Inc.

Retrieved on:

Wednesday, March 6, 2024

Attention, Goldman Sachs, J.P. Morgan & Co., TPH, Telephone, Scotiabank, Sale, Perella Weinberg Partners, Equity capital markets, Form, Broadridge Financial Solutions, BofA Securities, Roth Capital Partners, Security (finance), Evercore, Barclays, Form S-3

MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the pricing of an underwritten public offering of 11,500,000 shares of its Class A common stock (the “Secondary Offering”) by Viper’s parent, Diamondback Energy, Inc. (the “Secondary Stockholder”).

Key Points:

MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the pricing of an underwritten public offering of 11,500,000 shares of its Class A common stock (the “Secondary Offering”) by Viper’s parent, Diamondback Energy, Inc. (the “Secondary Stockholder”).
The Secondary Offering is expected to close on March 8, 2024, subject to customary closing conditions.
J.P. Morgan, Barclays, Evercore ISI and Goldman Sachs & Co. LLC are acting as joint book-running managers for the Secondary Offering.
The Secondary Offering may only be made by means of a prospectus supplement and related base prospectus.

Akero Therapeutics Announces Pricing of Public Offering of Common Stock

Retrieved on:

Wednesday, March 6, 2024

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share.

Key Points:

SOUTH SAN FRANCISCO, Calif., March 05, 2024 (GLOBE NEWSWIRE) -- Akero Therapeutics, Inc. (Nasdaq: AKRO), a clinical-stage company developing transformational treatments for patients with serious metabolic disease marked by high unmet medical need, announced today the pricing of an underwritten public offering of 11,000,000 shares of its common stock at a public offering price of $29.00 per share.
All of the shares in the offering are being offered by Akero Therapeutics.
In addition, Akero Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,650,000 shares of its common stock at the public offering price, less underwriting discounts and commissions.
The shares of common stock are being offered by Akero Therapeutics pursuant to an automatically effective shelf registration statement that was previously filed with the U.S. Securities and Exchange Commission (SEC).

Viper Energy Launches Secondary Common Stock Offering By Diamondback Energy, Inc.

Retrieved on:

Tuesday, March 5, 2024

Attention, Goldman Sachs, J.P. Morgan & Co., Telephone, Sale, Equity capital markets, Form, Broadridge Financial Solutions, Security (finance), Evercore, Barclays, Form S-3

MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the launch of an underwritten public offering of 11,500,000 shares of its Class A common stock by Viper’s parent, Diamondback Energy, Inc. (the “Selling Stockholder”), subject to market and other conditions (the “Secondary Offering”).

Key Points:

MIDLAND, Texas, March 05, 2024 (GLOBE NEWSWIRE) -- Viper Energy, Inc. (NASDAQ: VNOM) (“Viper”) announced today the launch of an underwritten public offering of 11,500,000 shares of its Class A common stock by Viper’s parent, Diamondback Energy, Inc. (the “Selling Stockholder”), subject to market and other conditions (the “Secondary Offering”).
Viper will not receive any proceeds from the sale of the shares by the Selling Stockholder.
The Selling Stockholder has also granted the underwriters a 30-day option to purchase up to an additional 1,725,000 shares of Viper’s Class A common stock.
J.P. Morgan, Barclays, Evercore ISI and Goldman Sachs & Co. LLC are acting as joint book-running managers for the Secondary Offering.

Akero Therapeutics Announces Proposed Public Offering of Common Stock

Retrieved on:

Monday, March 4, 2024

Varick Street, Attention, SAN, Jefferies Group, Prospectus, Telephone, 2nd Floor, Sale, Equity capital markets, DSM-IV codes, Broadridge Financial Solutions, Therapy, Morgan Stanley, Madison Avenue, Patient, Evercore, Jefferies, Security (finance)

All of the shares in the proposed offering are being offered by Akero Therapeutics.

Key Points:

All of the shares in the proposed offering are being offered by Akero Therapeutics.
In addition, Akero Therapeutics intends to grant the underwriters a 30-day option to purchase up to an additional $45.0 million of shares of its common stock at the public offering price, less underwriting discounts and commissions.
The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
J.P. Morgan, Morgan Stanley, Jefferies and Evercore ISI are acting as joint book-running managers for the proposed offering.